⌕
Enliven Therapeutics · ELVN · Nasdaq
Tenet 59 · Mixed
Compare
$47.62−2.42%At closeTenet 59 · Mixed
$47.62−1.18 (−2.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Enliven Therapeutics (ELVN) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 214 filers, Jun 30, 2026
# 13F FUNDS
214
13F VALUE
$4.1B
80.5M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 30, 2026Kunkel Lori AnnedirectorAcquired · Option exercise3,741$1.12↗
Oct 30, 2026Kunkel Lori AnnedirectorAcquired · Option exercise7,300$18.30↗
Oct 30, 2026Kunkel Lori AnnedirectorDisposed · Option exercise3,741Stock Option (right to buy)—↗
Oct 30, 2026Kunkel Lori AnnedirectorDisposed · Option exercise7,300Stock Option (right to buy)—↗
Oct 19, 2026Hohl BenjaminCHIEF FINANCIAL OFFICERAcquired · Option exercise6,018$14.85↗
Oct 19, 2026Hohl BenjaminCHIEF FINANCIAL OFFICERDisposed · Open-market sale6,018$38.48↗
Oct 19, 2026Hohl BenjaminCHIEF FINANCIAL OFFICERDisposed · Option exercise6,018Stock Option (right to buy)—↗
Oct 19, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERAcquired · Option exercise5,000$2.48↗
Oct 19, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERDisposed · Open-market sale5,000$38.47↗
Oct 19, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERDisposed · Option exercise5,000Stock Option (right to buy)—↗
Oct 14, 2026BALL KRISTINE MdirectorAcquired · Grant / award23,394Stock Option (right to buy)—↗
Oct 1, 2026Garland J. ScottdirectorAcquired · Option exercise13,000$15.47↗
Oct 1, 2026Garland J. ScottdirectorDisposed · Open-market sale13,000$46.67↗
Oct 1, 2026Garland J. ScottdirectorDisposed · Option exercise13,000Stock Option (right to buy)—↗
Aug 17, 2026Hohl BenjaminCHIEF FINANCIAL OFFICERDisposed · Open-market sale4,630$58.35↗
Aug 17, 2026Hohl BenjaminCHIEF FINANCIAL OFFICERDisposed · Open-market sale1,388$59.35↗
Aug 17, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERAcquired · Option exercise5,000$2.48↗
Aug 17, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERDisposed · Open-market sale3,900$58.37↗
Aug 17, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERDisposed · Open-market sale1,100$59.35↗
Aug 17, 2026Collins Helen LouiseCHIEF MEDICAL OFFICERDisposed · Option exercise5,000Stock Option (right to buy)—↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Enliven Therapeutics?

Enliven Therapeutics was held by 214 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.